Founded by John Burt, Medherant Limited is a clinical-stage pharmaceutical manufacturing startup that is revolutionizing transdermal drug delivery with its novel TEPI Patch® technology. The company has recently raised $3.7M from Mercia Asset Management PLC, and is developing innovative treatments using its advanced transdermal drug delivery system. Medherant's lead project is a testosterone patch for women, which promises greater convenience, confidence, and comfort for patients. By delivering drugs through the skin, the company's technology overcomes some of the disadvantages of oral administration, such as spikes in drug levels and poor compliance. 

The patches also provide better dose control than gels and creams. In addition to developing its own transdermal and topical products, Medherant is collaborating with third parties to formulate their drugs for transdermal delivery using its TEPI technology. With a focus on improving patient care through innovation in drug delivery, Medherant is poised to make a significant impact on the pharmaceutical industry.